Searching On:

Disease:

Gene:

FGFR2

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse FGFR2  - General Description FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival. In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer. Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway. FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival. In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer. Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway.
CLICK IMAGE FOR MORE INFORMATION
FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival.

In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer.

Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway.

FGFR is a gene that provides the code for making a protein called fibroblast growth factor receptor. This receptor is located on the surface of cells. FGFR has at least 4 subtypes, FGFR 1,2,3, and 4. When certain growth factors (proteins that stimulate cell growth and division) bind to an FGFR receptor, this activates a signaling system within the cell that causes the cell to undergo certain changes. In their normal role, the FGFR proteins play crucial roles in cell proliferation, migration, angiogenesis, and survival.

In certain types of cancers, genetic changes in the FGFR gene have been found. These changes include either amplification (more of the receptor is made than in normal cells), translocation (the gene has moved position such that it is under different regulation, causing more of the receptor to be made than in normal cells), or mutation (changes in the DNA that result in dysregulation of the protein, usually causing continuous activation of the receptor, even in the absence of growth factor). The excessive signaling that results from these genetic changes in number or activity level of the FGFR receptors contribute to abnormal cell growth and cancer. Unusual expression of the FGFR2 gene from various gene alterations has been found in some Breast cancers, Bladder cancers, Colorectal cancers, Esophageal/Gastric cancers, Endometrial cancers, Gall Bladder and Bile Duct (Cholangiocarcinoma) cancers, Glioblastomas, Head and Neck cancers, Lung cancers, Ovarian cancers, Pancreatic cancer, and Prostate cancer.

Preclinical testing in cancer cell lines suggest that FGFR gene alterations can be an important mechanism of tumor progression that may be effectively targeted with FGFR inhibitors. This has led to the development of clinical trials evaluating FGFR inhibitors in FGFR genetically altered tumors, with treatment of patients in these early studies underway.

PubMed ID's
24265351
Expand Collapse No mutation selected
The mutation of a gene provides clinicians with a very detailed look at your cancer. Knowing this information could change the course of your care. To learn how you can find out more about genetic testing please visit http://www.massgeneral.org/cancer/news/faq.aspx or contact the Cancer Center.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene
Trial Status: Showing all 5 results Per Page:
Protocol # Title Location Status Match
NCT01872260 Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer MGH Open G
NCT02734615 Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers MGH Open G
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer MGH Open G
NCT02732119 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. MGH Open G
NCT01948297 Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations MGH Open G
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 5 results Per Page:

Share with your Physican

Print information for your Physician.

Print information